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Summary 
We investigated the role of the complementarity  determining region 1 (CDR1) of T cell receptor 
(TCR)/3 chain both in antigen/major histocompatibility complex I (MHC I) and in superantigen 
(SAg)/MHC II complex recognition. Residues 26 to 31 of the VB10 domain of a TCR derived 
from an  Hl2Ka-restricted cytotoxic clone were individually  changed to  alanine, using site- 
directed mutagenesis, and the mutated TCR/3 chains were transfected along with the wild-type 
TCR c~ chain into a TCRc~-/3-  T hybridoma. These mutations affected antigen/H-2K  a com- 
plex recognition, although to a different extent, as estimated by interleukin 2 production.  Certain 
mutations also affected differently the recognition of two Staphylococcal toxins, exfoliative toxin 
and Staphylococcal enterotoxin C2, presented by HLA-DR1. Whereas mutation of residues D30 
or T31 affect the recognition of both toxins, residues T26, L27, and H29 are critical for the 
recognition of only one of the SAgs. These observations demonstrate the participation  of the 
CDR1 region in the recognition of peptide/MHC class I as well as SAg/MHC II complexes. 
U 
nlike Igs, which can recognize antigen in its native form, 
the TCR recognizes a peptide that is the product of 
antigen processing and that is trapped in the groove of the 
MHC molecule on the plasma membrane of a presenting cell 
(for a review, see references 1 and 2). However, the organiza- 
tion of rearranging gene elements and the primary amino 
acid sequence of the TCR are similar to those of Igs (3, 4). 
The conservation in c~ and/3 TCR chains of residues found 
to be crucial for the structure of the Ig variable domains, 
suggests that the three-dimensional  structure of the TCR 
is similar to the known atomic structure of the Fab moiety 
(5). By analogy to the antigen binding site on Ig, three regions 
of TCR o~ and/3 chains, which are hypervariable and which 
correspond to the loops formed between/3 sheets, are named 
CDR1, CDR2, and CDR3. The last one is encoded by the 
V-(D)-J junction in cx and/3 TCR chains and is therefore 
the most variable one, whereas CDR1 and CDR2 are en- 
coded in the genome by the V segment. A fourth hypervari- 
able region (CDR4) was identified in the TCR/3 chain (6, 7). 
Based on this model of TCR structure and the known 
crystal structure of several HLA molecules, different groups 
(4-6) have  proposed that the less variable CDR1 and CDR2 
regions might make direct contact with the MHC molecules 
whereas the CDR3 region might make direct contact with 
the antigenic peptide. Consistent with this model, mutations 
of the CDR regions, especially in CDR3, cause a loss of rec- 
ognition of the antigen/MHC complex (8-12). However, to 
our knowledge, all of the data available until now concern 
TCR restricted  to class II MHC molecule. 
In the past few years, a distinct group of antigens has been 
described and termed superantigens (SAg)  1 (for a review see 
reference 13). Several exotoxins of Staphylococcus aureus have 
superantigenic properties: activation of subsets of T cells ex- 
pressing particular V/3 families and presentation in a site of 
the MHC class II molecule distinct from the peptide-binding 
pocket, in the absence of processing and of absolute allotype 
restriction (14). Several  studies have led to map critical residues 
for SAg recognition to the lateral solvent-exposed face of the 
1 Abbreviations used in  the paper: ExT, S.  aureus exfoliative toxin;  SAg, 
superantigen; SEC2, S. aureus enterotoxin C2; SN, supernatant; wt, wild 
type. 
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there is recent evidence that other components of the TCK 
may also contribute to the interaction with the SAg/MHC 
complex (20-23). Moreover, although it is generally assumed 
that the surface of the TCK that engages MHC in the com- 
plexes with SAg is the same one that contributes to MHC 
binding in conventional peptide/MHC complexes,  experi- 
mental data for this point are scarce. 
The results obtained in this study identified residues in the 
Vfll0 chain CDR1 region of a H-2Kd-restricted TCR that 
are important both for specific peptide/MHC class I and/or 
SAg/MHC class II complex recognition. 
Materials and Methods 
Transfecting Cells andPlasmids.  The 58 TCR ce-~- cell line de- 
rived from DO.11.10 T hybridoma was previously  described (24). 
It was transfected by electroporation with plasmid pCA208 con- 
taining the Lyt2.2 gene and thegpt selective  marker (25). Sdection 
was done in the presence of mycophenolic acid (2.0 #g/ml), xan- 
thine (250 #g/ml) and hypoxanthine (15 #g/ml). After cloning 
and subdoning, one CD8 + done denoted 3D1 was selected for 
transfection with cDNAs encoding the wild type (wt) or mutated 
(see below) Cw3/1.1 TCR c~ and ~ chains. A full-length cDNA 
corresponding to the TCIL ce chain present in Cw3/1.1 cytotoxic 
clone (26) was subdoned into the SalI/BamHI opened plasmid 
pHBAPr-l-neo (27). Similarly,  a fuiLlength cDNA corresponding 
to  the  TCR  ~  chain found  in  Cw3/1.1  was  subcloned into 
SalI/BamHI opened plasmid pHBApr-l-neo. To facilitate further 
handling of the TCR VB region, an XhoI site was engineered at 
the J~/CB junction. This process resulted in the substitution of 
an isolencine (ATA) by a leucine (CTC) at position 116A (see Fig. 
1).  Linearized plasmids pH~Apr-l-neo/Cw3~ and pH~APr-1- 
neo/Cw3~ were cotransfected with plasmid pCA262 containing 
the cDNA of  murine CD3 ~'chain  (28). Transfectants  were selected 
in 1.6 mg/ml of geneticine G418-sulfate (GIBCO BRL, Gaithers- 
burg, MD) and screened for TCR expression by flow cytometry 
with a FITC-conjugated  anti-CD3 mAb (2Cll, Pharmingen),  using 
a FACScan  |  (Becton  Dickinson & Co., Mountain View, CA). Sub- 
clones expressing  high levels of TCg were isolated  by flow cytom- 
etry sorting using 2Cll-FITC anti-CD3 mAb (Pharmingen, San 
Diego, CA) in a FACStar  |  (Becton Dickinson & Co.). 
Electroporation Conditions.  10  y T hybridoma cells, resuspended 
in 0.8 ml Hepes buffered saline, were given a single pulse (240 V, 
192 fJ, 900 #F), in 4-ram cuvettes at room temperature, using a 
Cellject (Eurogentec S.A., Sart Tilman, Bdgium) apparatus. Cells 
were immediately  resuspended  in 40 ml of  complete 10% FCS RPMI 
1640  (GIBCO  BRL).  Selection medium  was  added 48  h 
later, plating 105 cells/well in 24-well plates (Costar Corp., Cam- 
bridge, MA). 
Site-directedMutagenesis ofTCR V~.  The full-length Cw3 TCR 
cDNA  was  introduced  into  the  SalI-BamHI open  plasmid 
pBSK* (Stratagene, La Jolla, CA). The VB10-D~I-J~I.2 segment 
was then excised using SalI and XhoI restriction enzymes, from 
plasmid pBSK+Cw3~. The purified fragment served as template 
in recombinant PCR, as previously  described (29), for the genera- 
tion of the single residue Ala-substituted mutants of the CDR1 
fl region. The SalI/XhoI-digested PCIL products were cloned into 
the Sall/XhoI-digested  and -purified pBSK§  containing 
the TCR fl constant region. After sequencing, mutant (as well 
as wt) Cw3 TCR fl cDNAs were subcloned into the SalI/BamHI 
site of the expression vector pH APr-l-neo (27). 
Antibodies.  2Cll-FITC (anti-CD3) mAb and H57-biotinylated 
(anti-Cfl) mAb were purchased from Pharmingen, and 53-6.7-FITC 
anti-Lyt2 mAb from Becton Dickinson & Co. Anti-Vfll0 and anti- 
V~8 stainings were done with supematants of B21.5 and B21.14 
hybridomas, respectively  (30), using fluorescein-conjugated  mouse 
anti-rat antiserum from Immunotech (Marseille, France), as sec- 
ondary reagent. 
Activation of Transfected  Clones.  Transfectants  were grown in com- 
plete 10% FCS RPM11640 (GIBCO BRL) without G418 for 48 h 
before assay. 105 irradiated H-2K  d expressing P815 cell line (10,000 
tad) were plated into 96-well plates (Costar Corp.) and incubated 
for 3 h with 10 -4 M Cw3(170-179) peptide (Neosystem Labora- 
tories SA,  Strasbourg, France) at 37~  105 transfected TCR § 
clones were then added in triplicates. Alternatively, 105 transfected 
clones were plated into 96-well microcuhure plates (Costar Corp.) 
previously incubated at 4~  overnight with purified 2Cll (anti- 
CD3) or H57 (anti-Cfl) mAbs at the indicated concentrations, or 
with 10/~g/ml of  mouse anti-rat antiserum (Immunotech), washed 
three times with PBS, and then incubated for 1 h with complete 
medium (10% FCS) or with anti-VB10 (B21.5) rich supernatant, 
respectively. In some  cases, PMA (Sigma Chemical Co., St. Louis, 
MO) was added in a final concentration of 10 ng/ml. The T hy- 
bridoma 9.4, product of the fusion of the CD8 + cytotoxic clone, 
Cw3/1.1 with the 58 TCK cx-fl- hybridoma was used in SAg- 
induced activation  assays.  L cells transfected  with HLA-DRBl*1102 
(L625.7), DRB1"1101 (L581.13), DRB*1301 (I,597.2), DRB1"1101 
F671  (L620.2), DRBl*1104 F67I (L663.5),  and  DRBI'D02 
(L650.2) (31) were a gift ofR. W. Karr (Monsanto Co., St. Louis, 
MO). DRBl*1101 F67I and DRB1*1104 F67I are mutants in which 
phenylahnine at position 67 in the DR/3 chain was changed into 
isoleucine (Karr, K. W., unpublished observations). L cells trans- 
fected with HLA-DRBI'0101  (DAP3-DR1) (32) were provided 
by E. Long (National Institutes of  Health, Rockville, MD). L cells 
transfected with HLA-DR were used in SAg-induced activation 
at 105 cells/well. S. aureus enterotoxin C2 (SEC2) and S. aureus ex- 
foliative toxin (ExT) (Toxin Technology Inc., Sarasota, FL) were 
added at 10 #g/ml final concentration, followed  by 105 transfected 
T hybrids clones. Cultures were maintained at 37~  in a 5% CO2 
humid atmosphere. Supernatants (SN) were harvested 24 h later 
and freezed before testing. 
Ib2 Assay.  104 CTLL-2 cells per well were cultured in 100 #1 
of media containing 20% of conditioned SN or different doses of 
a rlL-2-rich SN in 96-well microculture plates (Costar Corp.). 
Proliferation was assessed by [3H]thymidine  incorporation and Ib2 
U estimated as previously described (33). 
Normalization  of the Activation Responses.  The relative antigen 
(or SAg) recognition index, (estimated by I1.-2 production) was 
calculated as previously described (11) with some modifications. 
Briefly, the following antigenic recognition index (ARI) was cal- 
culated: ARI = equivalent [mAb] antigen (or SAg)/[mAb] 50% 
maximum, where equivalent [mAb] antigen (or SAg) is the equiva- 
lent concentration of the anti-TCR mAb (2Cll, anti-CD3 or H57, 
anti-C~) that gives the same IL-2  release as the antigenic (or super- 
antigenic) stimulus, and [mAb] 50% maximum, is the concentra- 
tion of the anti-TCR mAb that gives 50% of maximal response. 
The results are expressed as the percentage of the above calculated 
ARI index for the mutant transfectant in relation to the calculated 
ARI index for the wt. 
Results 
The Cw3/1.1  TCR and the T Hybridoma Transfection System. 
The TCR studied here was derived from a CD8 + cytotoxic 
done, Cw3/1.1, originally  obtained by immunizing a DBA/2 
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Figure  1.  Outline  structure  of the Cw3/1.1  TCR.  (A)  Schematic 
representation  of the TCIL o~ and B chains. (B) Partial protein sequence 
of the TCR-/~ chain. CDR1, CDR2, and CDR3 regions are underlined. 
Single-letter  code for amino acid residues. (Arrows)  Borders of the V, J, 
and C  regions;  (dotted line) probable  N-region sequences. 
mouse (H-2  a) with a P815 cell line transfected  with HLA- 
Cw3 (P815-Cw3)  (26). The fine specificity of the Cw3/1.1 
TCR for the Cw3 (170-179) peptide presented by H-2K  d has 
been described (26). Based on the predicted structure of the 
TCR V region (5), the CDR1 region of the Cw3/1.1 TCR 
V/~ chain should lie between residues 26 and 31 (numbered 
according  to  reference  34).  The relevant  features  of the 
Cw3/1.1 TCR, including the amino acid sequence of its V/~10 
segment, are displayed in Fig.  1. Note that the last residue 
of the JB1.2 segment, an isoleucine, was replaced by a leu- 
cine in order to create an XhoI site, which allowed the exci- 
sion of the VDJ(~ segment for mutagenesis. This conserva- 
tive change is not likely to affect the specificity of the Cw3/1.1 
TCR, inasmuch as leucines are found at very high frequency 
at this position (34). 
The expression of the accessory molecule CD8cr was shown 
to be necessary, in some cases, to endow a recipient T  hy- 
bridoma with the specificity of the transfected CTL-derived 
TCR (25). To optimize specific  recognition, we therefore trans- 
fected the genomic DNA of the CD8o~ molecule into the 
T hybridoma 58 o~-/~- (24). The cDNAs corresponding to 
the wt or mutated TCR/~ chain were then transfected into 
the established CD8 + TCR (x-/~- 3D1 subclone,  together 
with a wt TCR o~ chain cDNA. 
The CD3 J'chain constitutes a limiting factor for the trans- 
port of the TCR complex to the plasma membrane (35). To 
reach high levels of TCR expression in the 3D1 subclone, 
and because  58 c=-/~-  expresses low levels of endogenous 
CD3 ~" (Malissen,  B., unpublished observation), a plasmid 
driving the expression of the CD3  ~" chain was systemati- 
cally cotransfected with the ones driving TCR o~ and/~ chains 
expression  (data  not shown). 
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Figure  2.  Surface  expression of CD8 and TCR./CD3 mol- 
ecules in the T  hybridoma  transfectants  as assessed by flow 
cytometry.  Recipient (dotted lines) and Cw3/1.1 TCR trans- 
fected cells (solid lines) were stained with antibodies: (top left) 
53-6.7-FITC (anti-CD8);  (top right) 2C11-HTC (anti-CD3~); 
(bottom left) H57-biotinylated  (anti-Cfl),  followed by labeling 
with streptavidin-phycoerythrin;  (bottom  left)  B21.14 (anti- 
Vow8), followed by fluorescein-conjugated mouse anti-rat an- 
tiserum. 
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2Cll (which recognize an epitope on the CD3 e chain), H57 
(which is specific for the C region of the ~/chain), and an 
anti-Va8:B21.14 (30). Fig. 2 shows the FACS  |  profiles of 
the WT.27 clone expressing a wt TCR after staining with 
mAbs directed to the CD8a, CD3e, Cfl, or Vc~8 molecule 
domains. Clones expressing the same or higher amounts of 
CD8 and TCR than the wt TCR transfectants, were kept 
for further assays. 
We also used a fourth mAb, B21.5, which discriminates 
between the two allelic  forms of  mouse VB10 (30). This mAb 
recognizes Vfll0  b, which differs from Vfll0  ~  at positions 11, 
14, 24, 28, 30, and 84 (36) (numbered according to reference 
34). All the Vfll0  b CDR.1 mutants described here are rec- 
ognized by the anti-Vfll0  b mAb (data not shown). This ob- 
servation suggests that the alanine substitutions do not cause 
major change in the VB10 structure and that the CDR1 
residues 28 and 30 do not contribute to the epitope defined 
by mAb B21.5. 
The Effect of Alanine Substitution in the Cw3/1.1  TCR fl 
Chain on Anti-V~IO mAb-induced Activation.  To check their 
functional capabilities, mutants were first  tested  for IL-2 
production induced by different doses of plate-immobilized 
mAb. All mutants could be activated in this way to produce 
IL-2 when induced by an anti-Cfl mAb (H57).  Moreover, 
the different CDR1 fl mutants, with the exception of G28A, 
displayed a similar pattern of activation when induced by anti- 
Cfl or anti-Vfll0 mAbs, comparable with that observed for 
the wild type TCR transfectants, as shown in Fig. 3. Al- 
though mutant G28A is recognized by B21.5 mAb as well 
as the other mutants (data not shown), it was found to be 
more sensitive to anti-Vfll0 mAb-induced activation. These 
results further support the notion that the alanine substitu- 
tions did not grossly disrupt the structure and function of 
the mutated TCR. 
Specific Peptide/MHC I Recognition by the Cw3/1.1  TCR 
~Mutants.  The mutants were further tested for IL-2 produc- 
tion upon presentation of the Cw3(170-179) peptide by the 
H-2Kd-expressing P815 cell line. Only T26A and L27A mu- 
tants gave detectable responses (Table 1). The amount of IL-2 
secreted by mutants G28A, H29A, D30A, and T31A were 
<0.07-0.16  U/ml, the minimum detectable level, depending 
on the experiment.  As detailed in Materials and Methods, 
we normalized the response to the Cw3 peptide/K  a of each 
tested done in relation to its response to one anti-CD3 (2Cll) 
or one anti-Cfl (H57) mAb. In an attempt to maximize the 
T hybridoma response, 10 ng/ml of PMA was added to the 
cultures. This increased the IL-2 secretion in response to an- 
tigen or anti-TCIL mAbs 2-10-fold. Nevertheless,  IL-2 produc- 
tion by the G28A, H29A, D30A, and T31A mutants in re- 
sponse to Cw3 peptide/K  d was not detectable even in the 
presence of PMA (Table 1). In summary,  alanine substitu- 
tions at CDR1 B positions  26 or 27 partially reduced the 
peptide/MHC recognition, whereas substitutions at positions 
28, 29, 30,  and 31 abolished recognition in our system. 
Superantigen-induced Activation of Cw3/1.1  TCR ~  Mu- 
tants.  We next tested the effect of the alanine substitutions 
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Figure 3.  Responses to anti-C3 and anti-V3 mAbs by wt and CDR13 
mutant transfectants. The IL-2 secretion by clones expressing the indicated 
TCK was measured in response to the indicated amounts (top) of immobi- 
lized H57 anti-C~ mAb (squares) or ofB21.14 anti-V~10  mAb (circles, bottom 
ax/s). Results are representative of three experiments. 
on SAg/MHC II recognition. Three exogenous SAg have 
been described as activators of V~10 in the mouse (14): SEA, 
SEC2, and ExT, all of them S. aureus toxins. In our hands, 
SEC2 and ExT, but not SEA, induced IL-2 secretion in wt 
Cw3/1.1 TCR-bearing clones, when presented  by L cells trans- 
fected with HLA-DR1 molecule. The results obtained  are 
shown in Table 2. Responses to SAg were normalized with 
respect to the activation induced by anti-C~/mAb, as above. 
All the CDR1 mutants, with the exception of G28A, have 
a reduced response to at least one of the superantigenic stimuli. 
It is interesting to note that whereas the alanine substitu- 
tions at positions  26 or 29 severely affected SEC2 recogni- 
tion, substitution at position 27 almost abolished the response 
to ExT, without affecting SEC2 recognition. On the other 
hand, the recognition of SEC2 and ExT by mutants D30A 
1090  V~ CDR1 of MHC I-restricted TCR Recognizes Peptide/MHC I and SAg/MHC II Table  1.  Recognition  of Cw3 peptide (170-179)/K  d Complex by CDRI~ Mutants* 
Anti-TcK  Anti-TCK 
giving 50%  of max.  equivalent  to Cw3/Kd 
Type  Clone  IL-2 release  response 
Relative 
responses 
~,g/ml  ~,g/ml 
Exp.  1  T26A  21.8  5.84~  0.76 
wt  wt.27  21.29  16.34 
Exp.  2  T26A  21.24  1.54  0.10 
wt  wt.20s4  1.03  0.43 
Exp.  1  L27A  32.5s4  17.49  1.53 
L27A  32.5s33  11.88  1.52 
wt  wt.20s4  8.16  6.16 
Exp.  2  L27A  32.25s7  0.29  0.01 
wt  wt.27  5.72  1.68 
Exp.  1  G28A  51.5sl  1.85  NS 
G28A  51.5s14  1.68  NS 
G28A  51.29s6  5.20  NS 
G28A  51.29sll  5.00  NS 
wt  wt.27  5.72  1.68 
Exp.  2  G28A  51.5s15  1.63  NS 
G28A  51.29s13  5.81  NS 
wt  wt.20s4  3.42  2.51 
Exp.  1  H29A  4.1/31s5  1.85  NS 
H29A  4.1/31s4  16.70  NS 
wt  wt.27  21.29  16.34 
Exp.  2  H29A  4.1/20  6.65  NS 
H29A  4.1/56  9.73  NS 
H29A  4.1/3  12.51  NS 
wt  wt.27  6.72  14.50 
Exp.  1  D30A  62.16  5.82  NS 
D30A  62N13s19  6.71  NS 
wt  wt.27  5.72  1.68 
Exp.  1  T31A  72.N2  1.95  NS 
wt  wt.20s4  1.95  1.20 
% 
16.9 
100.0 
15.4 
100.0 
11.6 
16.9 
100.0 
14.3 
100.0 
NS 
NS 
NS 
NS 
100.0 
NS 
NS 
100.0 
NS 
NS 
100.0 
NS 
NS 
NS 
100.0 
NS 
NS 
100.0 
NS 
100.0 
" 10  s CDRI~/mutated or wt transfectants were cocultured with  105 K  d+ P815 cells, in the presence of 10 -4 M 
ng/ml of PMA, for 24-36 h. I1.,2 production was estimated in a CTLb2 assay. 
Anti-C~ (H57) or anti-CD3 (2Cll)  mAbs were plated at 30.0-0.0137/~g/ml,  after a threefold dilution. 
S The relative antigenic response was calculated as described in Materials and Methods. 
of Cw3 (170-179) peptide and 10 
and T31A is reduced to the same extent, D30A having more 
pronounced effects.  A summary of the data is shown in Fig. 4. 
SAg Presentation by Different HLA-DR Alleles.  To obtain 
more information about TCR/SAg-MHC II interaction, pre- 
senting cells expressing other MHC II molecules were used 
for SAg presentation. Fibroblast L cell lines transfected with 
different  alleles  of HLA-DK  (DRB1*1101,  DRB1*1102, 
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DRB1*1301,  DILB1*1302),  or  with  mutated  HLA-DR 
(DRBl*1101  F67I and DRBl*1104  F67I) (31)  were tested 
for ExT and SEC2 presentation  to the wt Cw3/1.1  TCK- 
bearing hybridoma 9.4. Results are shown in Table 3. Three 
of these HLA-DK molecules were ineffective (DRB1*1301, 
DRB1*1302) or very poor presenters (DILBl*1102) for SEC2 
and  ExT  to  the  VB10 +  9.4  hybridoma,  although  all  of Table 2.  SAg/MHC Complex Recognition by CDRI/~ Mutants* 
Anti-TCR  Anti-TCR  Anti-TCR 
giving 50%  of max.  equivalent  to SEC2  equivalent  to ExT 
IL-2 release  response  response 
Relative response 
to SEC2 and 
ExT, respectively 
ng/ml  ng/ml  ng/ml 
Exp.  1  T26A  1,647,  149.0  149.0 
wt  1,881  ~54.0  194.0 
Exp.  2  T26A  1,490  32.0  291.0 
wt  2,448  136.0  776.0 
Exp.  1  L27A  548  128.0  0.8 
wt  1,881  454.0  194.0 
Exp.  2  L27A  95  14.0  1.4 
wt  963  131.0  103.0 
Exp.  1  G28A  2,460  1,130.0  1,290.0 
wt  1,457  370.0  400.0 
Exp. 2  G28A  760  272.0  133.0 
wt  1,472  333.0  136.0 
Exp.  1  H29A  3,010  423.0  402.0 
wt  1,881  454.0  194.0 
Exp.  2  H29A  4,100  524.0  963.0 
wt  2,448  136.0  776.0 
Exp.  1  D30A  833  9.1  10.7 
wt  1,881  454.0  194.0 
Exp. 2  D30A  624  1.5  10.3 
wt  2,448  136.0  776.0 
Exp.  1  T31A  5,959  ND  370.0 
wt  1,457  370.0  400.0 
Exp.  2  T31A  3,106  383.0  144.0 
wt  1,472  333.0  136.0 
% 
37  87s 
100  100 
4  62 
100  100 
97  1.4 
100  100 
112  14 
100  100 
181  189 
100  100 
158  190 
100  100 
58  130 
100  100 
23  74 
100  100 
5  12 
100  100 
1  5 
100  100 
ND  23 
100  100 
54  50 
100  100 
* 10  s CDR1/~ mutated or wild type transfectants were cocultured with 10  s DR-transfected L cells, in the presence of 10/~g/ml 
toxins, for 24-36 h. IL-2 production was estimated in CTLL-2 assay. 
Anti-Cfl (H57) or anti-CD3 (2Cll) mAbs were plated at 30.0-0.0137/~g/ml, after a threefold dilution. 
$ The relative superantigenic response was calculated as described in Materials and Methods. 
of SEC2 or ExT 
the  HLA-DR  transfectants  were  effective in  stimulating 
the  V~/1 +  and VBS.2 + DO.11.10  T  hybridoma (data  not 
shown). The analysis  of the polymorphic residues lying on 
the cr  of the MHC II molecules shows a correlation 
between the presence of arginine at position 71 and a significant 
level of IL-2 secretion, suggesting that the arginine at posi- 
tion 71 is critical for the recognition of the complex HLA- 
DR/ExT or SEC2 by the Cw3/1.1  TCR. 
An Ig  V. Model for the  TCR  V~ Domain.  Using  the 
alignment  of Chothia  et  al.  (5),  the  mutated  residues  of 
the VfllO domain were mapped on the known structure of 
the V  heavy domain of the D1.3 Ig (37),  as shown in Fig. 
5. The residues that specifically affect the recognition of SEC2 
or ExT (T26, L27, and H29) are predicted to lie in the part 
of the CDR1  loop  that faces the CDR4 region, whereas 
residues D30 and T31 which affect  recognition of  both toxins, 
are at the COOH-terminal end of the CDR1 region, closer 
to the CDR2 and CDR3 loops. 
Discussion 
In the absence of direct structural data, several groups (4-6) 
have proposed models of the TCR/peptide/MHC complex, 
in which the more variable CDR3 loops of the ol and B TCR 
chains contact the peptide lying in the groove of the MHC 
molecule, whereas the CDR1 and CDR2 loops contact the 
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a-helices of MHC. Several studies support a role for critical 
contacts between  peptide  and  CDR3  ol  and  ~  residues  of 
the TCR (for a review see reference 2). Indirect evidence sug- 
gesting contacts between TCR and MHC molecules has been 
obtained  by  mutating  MHC  residues  (38-42).  Multiple 
residues  on  one or both  ol-helices  of the  MHC  molecules 
are likely to be simultaneously recognized by the TCR, but 
the  sites of these interactions  are not  fixed,  since different 
TCRe specific for the same peptide/MHC  complex can be 
differentially affected by mutations of MHC residues (38, 40, 
42). The nature of the MHC/TCR  interaction has also been 
investigated  by  mutating  the  CDR  regions  of the  TCR 
(10-12).  Recently, Nalefski et al. (11) have systemically mu- 
tated the CDR1, CDR2,  and CDR3 regions of the o~ chain 
of a class II MHC-restricted TCR.  Residues important for 
peptide/MHC recognition were identified in all three CDR 
o~ regions. A concurrent model (43) predicts that SAgs bind 
Figure  4.  Mutations of CDRI~ residues affect peptide and SAg recog- 
nition to a different extent. The SAg (a) or antigen (b) recognition index 
of the CDR1 B mutant transfeetants  was calculated as described in Materials 
and Methods and expressed  as a percentage of the wt index. Bars indicate 
the mean of independent experiments and symbols the relative index of 
each experiment SEC2 (filled circles and open bars), ExT (filled triangles and 
filled bars), Cw3 (170-179) peptide (filled squares and filled bars). (Single open 
square) Experiments in which no antigen response was detected. Results 
are averaged  from the same  experiments as those described in Tables 1 and 2. 
Table  3.  SAg  Presentation  by Different  HLA-DR  Alleles* 
DR/3  chain 
polymorphic residuesS  IL-2 secretionLI 
APC*  (HLA-DK allele)  58  67  70  71  86  ExT  I  SEC2 
U/ml 
DP3-DR1  (DRB1*0101)  A  L  Q  R  G  32.3  30.2 
L625.7  (DRBl*1102)  E  I  D  E  V  4.1  1.2 
L650.2  (DRBl*1302)  A  I  D  E  G  <0.4  0.4 
L597.2  (DRBl*1301)  A  I  D  E  V  <0.4  <0.4 
L663.5  (DRB1*1104  F67I)  E  I  D  R  V  28.2  44.2 
L620.2  (DRB1*1101  F67I)  E  I  D  g  G  33.4  41.2 
L581.13  (DRB1 * 1101)  E  F  D  R  G  36.1  38.9 
* The murine 9.4 T hybridoma expressing the wild type Cw3/1.1 TCR (V~10 +) was activated by toxin SAg, as described in Materials and Methods. 
The results of one out of three independent experiments is shown. The murine T hybridoma DO. 11.10 (VB1  + and V~8.2 +), that express equiva- 
lent levels of the TCR/CD3 complex, respond to ExT and SEC2 secreting significant amounts of IL-2 (>50 and >290 U/ml, respectively) presented 
by all the HLA-DR alleles tested. 
* L fibroblasts transfected with different HLA-DR alleles (31) were used as presenting cells. All L cell lines express similar levels of HLA-DR (data 
not shown). 
$ Only polymorphic residues lying on the c~-helices of the DRB chain are shown.  Sequences are from reference 54. 
11 II.-2 production was measured using the CTLL-2 assay, as described in Materials and Methods. The IL-2 secreted in response to L cells alone equal 
CTLL background in all experiments. 
ExT and SEC2 were used at  10/xg/ml final concentration. 
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Figure 5.  The predicted  localization of the mutated V~810 residues based 
on Ig. The diagram of the c~ carbon skeleton of the V, domain was gener- 
ated with the coordinates of the x-ray crystallographic  analysis of the D1.3 
mAb (37), using MolDraw software (53). The predicted positions of the 
VB10 mutated residues were obtained using the alignment of Chothia et 
al. (5). 
laterally to the MHC II molecule (at a distance from the pep- 
tide binding groove) and to the lateral exposed face of the 
V/3 domain, promoting contact between TCR and MHC 
surfaces. Experimental  data on exogenous SAg binding to 
MHC molecules (44) and on the role of the Vfl CDR4 re- 
gion in SAg recognition (for reviews see references 45 and 
46) have provided some support  to these predictions.  Evi- 
dence for the involvement of other components of the TCR 
during SAg/MHC  II  complex recognition has  also been 
reported (20-23). 
The role of the TCR/3 CDR1 region in the recognition 
of both peptide/MHC I and SAg/MHC II complexes by a 
class I-restricted TCR thus far had not been evaluated, and 
was the purpose of this study. By site-directed mutagenesis, 
we prepared alanine substitutions  at all CDR1 positions of 
a V/3 domain and the mutants were transfected into an ap- 
propriate  hybridoma. All mutants could be expressed at a 
comparable level, and it appears unlikely that the alanine sub- 
stitutions  in the CDR1 13 region disrupted the overall con- 
formation of the TCR for several  reasons. In general, protein 
structures  appear quite stable with regard to alanine single 
point substitutions, especially  in loop structures (47, 48). The 
most profound effects on ligand binding are invariably found 
1094 
with mutations alterating ligand-contacting residues (47). The 
fact that all the CDR1 mutants (except G28A) responded 
to an anti-V/J10 mAb in the same dose-dependent  way as 
to an anti-Cfl mAb, strongly suggests that the overall struc- 
ture of the TCR is conserved. Further evidence that alanine 
mutation in residues T26, L27, and H29 is not causing con- 
formational changes, is the fact that mutations at these posi- 
tions have no effect on the recognition of at least one of the 
SAg tested. 
We first analyzed the recognition of the complex made 
of K d and  a  specific peptide.  This  revealed that  all  the 
residues of the CDR1/3 region are substantially involved, 
in particular residues 28 to 31, the mutation of which com- 
pletely disrupted recognition. A role for the charged (H29 
and D30) and polar (T31) residues is compatible with previous 
observations based upon the occurrence of individual amino 
acids in presumptive  functional  subregions of the TCR o~ 
and B chains and class I MHC molecules (49). The results 
suggested that the interaction between TCR and MHC mol- 
ecules would be mediated mainly by charged and polar aro- 
matic residues. Histidines display a remarkably high occur- 
rence in the CDR1 ~  region (49). It is unlikely, however 
that these histidines are essential for the local conformation 
of the binding loop, at least in the TCR studied here, be- 
cause the alanine substitution  at residue H29 did not affect 
response to the ExT SAg. Glycine 28 may confer a greater 
flexibility to the CDR1 loop. Note that, although the G28A 
mutation abolished the specific  peptide/MHC I recognition, 
it significantly increased the responsiveness to an anti-VB10 
mAb and the recognition of both toxin-SAg/MHC II com- 
plexes. This result shows the different participation  of the 
G28 residue during the engagement of one or the other type 
of compIex. 
We then studied the recognition of SAg/MHC complexes 
by exposing the hybridomas expressing the various mutants 
to HLA-DR1 + cells and either SEC2 or Ext superantigens. 
All mutations (except G28A) diminished the recognition of 
at least one of the SAg/DR complexes. There are at least 
two possible explanations for which the CDR1/3 region could 
influence toxin recognition. First, recognition of SAg may 
be critically dependent on concomitant recognition of the 
MHC II molecule by the TCR. Second, the CDR1 region 
may contact SAg directly. The two hypotheses are not mutu- 
ally exclusive, and some residues of the CDR1/3 region may 
contact the MHC II molecule whereas others may contact 
the SAg. 
The SEC2 toxin has high homology to other S. aureus en- 
terotoxins, for which more data on MHC II binding and TCR 
recognition are available (15, 45). For the exfoliating toxins, 
however, the matter of relatedness is much less dear (14), 
and data on MHC II and TCR binding are scarce. SEC2 and 
ExT may bind to the same or overlapping sites on the MHC 
II molecules as demonstrated for other toxins (50). It is in- 
teresting to note that the analysis of SAg recognition by the 
mutants described here indicates that the recognition of SEC2 
and ExT by the Cw3/1.1 V~10 TCR does not involve the 
same CDR1 ~/residues. In fact, whereas the recognition of 
one of the SAg was not affected  by mutations at residues T26, 
V3 CDR1  of MHC I-restricted TCR Recognizes  Peptide/MHC I and SAg/MHC II L27,  and  H29,  the  recognition  of the  other  toxin  was 
significantly diminished by the same mutation. The unrelat- 
edness between SEC2 and ExT can explain these results. The 
direct contact between the CDR1 ~  region and toxin SAg 
was also suggested in a recent study (23). In addition,  evi- 
dence for different contact residues in the hypervariable re- 
gion 4 of V~/8.2 TCR for unrelated endogenous Mls  a and 
bacterial SAg has recently been obtained  (20). 
L cells transfected with the different HLA-DR alleles were 
used to present the ExT and SEC2 SAg to the wt Cw3/1.1 
TCR-bearing hybridoma 9.4. Both SAg could be presented 
to the V~10 + 9.4 hybridoma by DRBI*0101, DRBl*1104- 
F67I, DRBl*1101-F67I, and DRB1*1101, but not by DRBI* 
1102, DRBl*1301,  or DRBl*1302  (Table 3),  although  all 
of the different HLA-DR alleles were effective in presenting 
the  same  SAg  to  the  Vfl8+/Vfll + DO.11.10  hybridoma 
(data not shown).  Similar results were previously reported 
by Herman et al.  (51),  who have shown that  some class II 
molecules can present SAg to some T cells but not to others 
that have the proper TCR VB element. Since all HLA-DR 
molecules share a common cr chain, these results mapped an 
important  site for TCR/MHC II/SAg interaction to the 
chain of HLA-DR. Moreover, the usage of L cells transfected 
with different HLA-DR alleles to present ExT or SEC2 is 
evidence in favor of the role of arginine  71 of the ~  chain 
of HLA-DR in TCR/MHC II interaction during SAg rec- 
ognition (Table 3). Accordingly, the recently resolved crystal 
of the DR1 molecule (52) indicates that R71 might be oriented 
towards the peptide binding site and might also be accessible 
to the TCR. 
The observation that mutations at residues D30 and T31 
affect to an equal extent the recognition of both toxins, D30 
having more drastic effects, is compatible with the view that 
these CDR1 fl residues interact with the MHC II molecule. 
Residue D30 is a candidate for the interaction with R71 on 
the DR molecule, and we are presently investigating this pos- 
sibility. The great similarity of MHC dass I and II mole- 
cules,  and the fact that TCR bearing the same V~ elements 
can recognize both classes of molecules (2), make it possible 
that the same CDR regions of a TCR may be involved in 
both type of interactions.  So, it is possible that the same CDR1 
residues that may contact MHC II in the presence of the 
SAg, may also contact MHC I in the recognition  of pep- 
tide/K  a complex. Indeed, mutations on D30 and T31 affect 
both toxin-SAg recognition and also disrupt the recognition 
of the  Cw3  peptide/K d complex.  It  seems unlikely  to us 
that these two residues would be directly involved both in 
SAg and peptide contact. We thus suggest that in our system 
these residues are essential for interaction with both classes 
of MHC molecules. Whether all the CDR1 residues are con- 
tacting only the MHC dass I residues located on the top of 
o~ helices,  or also antigenic peptide residues in our system, 
needs further  investigation. 
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